Inozyme Pharma, Inc. Quarterly Earnings Per Share, Basic in USD/shares from Q2 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD/shares
Description
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Summary
Inozyme Pharma, Inc. quarterly/annual Earnings Per Share, Basic history and growth rate from Q2 2021 to Q3 2024.
  • Inozyme Pharma, Inc. Earnings Per Share, Basic for the quarter ending September 30, 2024 was -0.39 USD/shares, a 34.5% decline year-over-year.
  • Inozyme Pharma, Inc. Earnings Per Share, Basic for the twelve months ending September 30, 2024 was -1.54 USD/shares, a 14.1% decline year-over-year.
  • Inozyme Pharma, Inc. annual Earnings Per Share, Basic for 2023 was -1.37 USD/shares, a 23% increase from 2022.
  • Inozyme Pharma, Inc. annual Earnings Per Share, Basic for 2022 was -1.78 USD/shares, a 25.8% increase from 2021.
Earnings Per Share, Basic, Trailing 12 Months (USD/shares)
Earnings Per Share, Basic, Quarterly (USD/shares)
Earnings Per Share, Basic, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$2 $0 $0 -34.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$1 $0 $0 -25.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$1 $0 +$0.02 +5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$1 $0 $0 -6.45% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-12
Q3 2023 -$1 $0 +$0.09 +23.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$1 $0 +$0.03 +7.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$1 $0 +$0.31 +43.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$2 $0 Oct 1, 2022 Dec 31, 2022 10-K 2024-03-12
Q3 2022 $0 +$0.22 +36.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $0 +$0.15 +28.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$1 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q3 2021 -$1 Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$1 Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.